17 October 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing client Cancer Research UK. The project involves the development of Pharmacokinetic Pharmacodynamic (PK/PD)* model to simulate the exposure-response relationship for a novel oncology therapy to guide starting dose and dose range for an upcoming First in Human Study.
Dr Peter Sargent, CEO, commented: "We are delighted to have been awarded this new contract with one of our existing clients. This contract reflects the impact of the services we provide and our continued relationship with Cancer Research UK".
* PKPD modelling is a scientific approach used to describe and predict the relationship between drug concentration in the body (PK) and the corresponding biological or physiological effect (PD). This supports the prediction of what the optimum drug dose needs to be to enable a therapeutic effect whilst minimising levels of toxicity.
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
